Company Overview - BenQ BM Holding Cayman Corp., referred to as "BenQ Hospital Group," is a private for-profit comprehensive hospital group in mainland China, leveraging operational management experience from Taiwan [1] - The group currently operates two comprehensive hospitals: Nanjing BenQ Hospital, a tertiary A hospital and the first private hospital in Nanjing to receive this rating, and Suzhou BenQ Hospital, also a tertiary hospital certified by the Joint Commission International (JCI) [1] Listing Details - The company has submitted a hearing document for a potential listing on the Hong Kong Stock Exchange, with CICC and Citigroup as joint sponsors [1] - The funds raised from the IPO will be allocated for various purposes, including expansion and upgrading of existing hospitals, potential investments and acquisitions, upgrading the "smart hospital" system, and general corporate purposes [3] Services and Operations - Nanjing BenQ Hospital is recognized as a national chest pain center and a demonstration base for health management, providing integrated medical, teaching, research, and operational services [1] - Suzhou BenQ Hospital has established differentiated advantages in departments such as obstetrics and pediatrics, and offers palliative care services [1] - The group aims to enhance operational efficiency and medical service quality through refined management and adaptability to the Diagnosis-Related Group (DRG) payment system [1]

智通财经获悉，据港交所12月9日披露，明基医院集团股份有限公司(简称：明基医院)通过港交所主板 上市聆讯，中金公司、花旗为联席保荐人。 招股书显示，明基医院是中国内地一家民营营利性综合医院集团，目前拥有和运营南京明基医院和苏州 明基医院等两家民营营利性综合医院。根据弗若斯特沙利文的数据，以2024年总收入计，公司是华东地 区最大的民营营利性综合医院集团，于华东地区的市场份额为1.0%；以相同口径计，公司在全国民营 营利性综合医院集团中排名第七，于中国的市场份额为0.4%；以2024年的床均收入计，公司在中国内 地所有民营营利性综合医院集团中排名第一。 截至2025年6月30日，上述两家医院总建筑面积合计约40万平方米，总注册床位数1850张，拥有超1000 名医生的有经验团队，其中包括35名来自中国台湾和海外的专家。于2024年，公司的门诊就诊次数超 200万人次，年住院手术量超22,000例。 南京明基医院于2008年开始运营，2022年起获评三级甲等医院，是江苏省南京市首家获得三甲评级的民 营医院。根据弗若斯特沙利文的数据，以2024年总收入计，南京明基医院是中国第三大民营营利性综合 医院(其于中国的市场 ...

商报记者 曾润玥 通讯员 谢文竹 现代肿瘤医学的迅猛发展，正持续打破晚期癌症的"生命桎梏"。56岁的王先生（化名）确诊晚期肠癌并 伴肝转移时，曾因病情危重被判定无法耐受传统手术，生命仿佛进入"倒计时"。而杭州市第一人民医院 吴山院区（杭州市肿瘤医院）多学科综合治疗团队的精准介入，为他打破了"无解"困局，重新点亮生命 希望。 晚期肠癌伴肝转移，生命陷入至暗 今年六月，王先生毫无征兆地出现腹泻、腹胀、双腿浮肿等症状，硬撑近一个月后，身体状况急剧恶 化。来到杭州市第一人民医院吴山院区（杭州市肿瘤医院）肿瘤放射治疗科就诊时，他已持续发热、无 法进食，腹部隆起如鼓，双腿浮肿一按一个深坑，还伴有大量便血，情况十分危急。 检查结果令人震惊：肝脏MRI显示肝脏内布满肿瘤，最大肿瘤达到16×11厘米，且已侵犯肝静脉与门静 脉；肠镜检查发现，距肛门30厘米处有结肠菜花样肿物，几乎完全堵塞肠腔。 "病理检查确诊为晚期肠癌伴广泛肝转移，患者当时身体极度虚弱，根本无法耐受传统手术。"肿瘤放射 治疗科三病区主任戴慧主任医师回忆到。 尽管晚期肠癌的治疗技术在不断进步，但戴慧强调，肠癌早期发现后的治愈率可达90%以上，因此早诊 早治至关重要 ...

Core Viewpoint - Ming Chi Hospital Group is preparing for an IPO on the Hong Kong Stock Exchange, with CICC and Citibank as joint sponsors [1]. Company Overview - Ming Chi Hospital is a private for-profit hospital group in mainland China, operating two hospitals: Nanjing Ming Chi Hospital and Suzhou Ming Chi Hospital [3]. - The company is the largest private for-profit hospital group in East China by total revenue in 2024, holding a market share of 1.0% in the region and ranking seventh nationally with a market share of 0.4% [3]. - The company ranks first among all private for-profit hospital groups in mainland China in terms of revenue per bed for 2024 [3]. Hospital Operations - As of June 30, 2025, the two hospitals have a combined area of approximately 400,000 square meters and a total of 1,850 registered beds, supported by a team of over 1,000 experienced doctors, including 35 experts from Taiwan and overseas [3]. - In 2024, the hospitals are expected to serve over 2 million outpatient visits and perform more than 22,000 inpatient surgeries [3]. Nanjing Ming Chi Hospital - Nanjing Ming Chi Hospital began operations in 2008 and was rated as a Class III Grade A hospital in 2022, being the first private hospital in Nanjing to achieve this rating [4]. - It is the third-largest private for-profit hospital in China by total revenue in 2024, with a market share of 0.3% nationally and 2.0% in Jiangsu Province [4]. - The hospital has received multiple national certifications, including being a certified chest pain center and a national health management demonstration base [4]. Suzhou Ming Chi Hospital - Suzhou Ming Chi Hospital started operations in 2013 and is a Class III comprehensive hospital [4]. - It received JCI accreditation in 2020 and is recognized as a national chest pain center and a stroke prevention center [4]. - The hospital has developed unique advantages in departments such as obstetrics and pediatrics, and has been recognized as a "Jiangsu Province Elderly-Friendly Medical Institution" [4]. Financial Performance - The company reported revenues of approximately RMB 2.336 billion, RMB 2.688 billion, and RMB 2.659 billion for the years 2022, 2023, and 2024, respectively [5]. - The profit for the same periods was approximately RMB 89.55 million, RMB 167.45 million, and RMB 108.92 million [5]. - For the six months ending June 30, 2024, and 2025, the revenues were approximately RMB 1.330 billion and RMB 1.312 billion, with profits of RMB 63.40 million and RMB 48.70 million, respectively [5].

智通财经APP获悉，据港交所12月9日披露，明基医院集团股份有限公司(简称：明基医院)通过港交所主板上市聆 讯，中金公司、花旗为联席保荐人。 招股书显示，明基医院是中国内地一家民营营利性综合医院集团，目前拥有和运营南京明基医院和苏州明基医院等 两家民营营利性综合医院。根据弗若斯特沙利文的数据，以2024年总收入计，公司是华东地区最大的民营营利性综 合医院集团，于华东地区的市场份额为1.0%；以相同口径计，公司在全国民营营利性综合医院集团中排名第七，于 中国的市场份额为0.4%；以2024年的床均收入计，公司在中国内地所有民营营利性综合医院集团中排名第一。 截至2025年6月30日，上述两家医院总建筑面积合计约40万平方米，总注册床位数1850张，拥有超1000名医生的有 经验团队，其中包括35名来自中国台湾和海外的专家。于2024年，公司的门诊就诊次数超200万人次，年住院手术 量超22,000例。 南京明基医院于2008年开始运营，2022年起获评三级甲等医院，是江苏省南京市首家获得三甲评级的民营医院。根 据弗若斯特沙利文的数据，以2024年总收入计，南京明基医院是中国第三大民营营利性综合医院(其于中国的市 ...

Group 1 - The core viewpoint of the article highlights that ST Zhongzhu (SH 600568) held its 14th meeting of the 10th Board of Directors on December 9, 2025, via teleconference to discuss the proposal for the 2025 fourth extraordinary shareholders' meeting [1] - For the first half of 2025, ST Zhongzhu's revenue composition is as follows: hospital income accounts for 56.92%, real estate projects 25.88%, pharmaceutical industry 8.93%, medical devices 4.15%, and center cooperation 3.59% [1] - As of the report date, ST Zhongzhu's market capitalization is 5.3 billion yuan [1] Group 2 - The article also mentions a significant issue in the pharmaceutical industry regarding the abuse of pregabalin, marking the first reported case of addiction in China, highlighting vulnerabilities in online platforms that allow drug purchases without medical records [1]

Core Viewpoint - The establishment of the Cardiac Rehabilitation Professional Committee in Rizhao marks a significant step towards standardizing and enhancing cardiac rehabilitation services in the region, focusing on multi-center research, early severe rehabilitation practices, and talent cultivation [5][6]. Group 1: Committee Formation - The inaugural members of the Rizhao Cardiac Rehabilitation Professional Committee were elected, including 1 chairperson, 7 vice-chairpersons, and 42 committee members [3]. - Dr. Wang Yuanyuan, the director of the Cardiac Rehabilitation Center at Rizhao Heart Hospital, was elected as the chairperson of the committee [3]. Group 2: Development Consensus - Dr. Wang emphasized the committee's focus on five key areas: technical standards, multi-center research, early severe rehabilitation practices, center construction support, and talent cultivation [5]. - The establishment of the committee is expected to promote a scientific, unified, and standardized cardiac rehabilitation process across local medical institutions, aiding patients in safely and effectively rebuilding their physical and mental vitality [5][6]. Group 3: Academic Exchange and Regional Development - An academic forum was organized, where experts discussed new technologies in cardiac rehabilitation, heart failure rehabilitation, and cardiovascular disease management [8]. - Rizhao Heart Hospital has been dedicated to exploring and building cardiac rehabilitation since its establishment, achieving recognition as a national demonstration unit for cardiac rehabilitation centers [8]. - The committee's formation is seen as a new mission to lead the development of cardiac rehabilitation in the region, with a commitment to integrating quality resources and enhancing multidisciplinary collaboration [8].

Core Insights - The hospital has successfully passed the national-level grassroots chest pain center re-evaluation and has been approved as a national-level hypertension management center, marking a dual enhancement in cardiovascular disease emergency treatment and chronic disease management [1][3]. Group 1: Chest Pain Center - The chest pain center serves as a "green channel" for acute chest pain patients, directly impacting the success rate of treating high-risk conditions like acute myocardial infarction and aortic dissection [3]. - Since becoming a national-level chest pain center, the hospital has established a comprehensive collaborative treatment system integrating pre-hospital emergency care, in-hospital treatment, and post-operative rehabilitation, significantly reducing the "door-to-balloon time" to as fast as 23 minutes [3][5]. - The hospital reports a reperfusion treatment rate exceeding 95% for acute myocardial infarction patients at the chest pain center [3]. Group 2: Hypertension Management Center - The approval of the hypertension management center initiates a new phase in chronic disease management, focusing on the standardized management of hypertension, a primary risk factor for cardiovascular diseases [3][5]. - The hospital plans to implement a comprehensive management system that includes screening, diagnosis, treatment, and follow-up by integrating resources from various departments [5]. - Key features of hypertension management will include a combined Chinese and Western medicine assessment system, a smart management platform for real-time data upload and remote guidance, and regional collaboration to standardize management practices [5]. Group 3: Future Development - The hospital aims to enhance blood pressure control rates and provide standardized, precise Chinese and Western medicine combined treatment services locally [5]. - The acquisition of these national-level qualifications exemplifies the hospital's commitment to a balanced development of Chinese and Western medicine and serves as a testament to its high-quality discipline construction [5]. - The hospital intends to leverage this dual achievement to further solidify the chest pain center's accomplishments and accelerate the development of the hypertension management center through technological innovation and process optimization [5].

据媒体此前报道，有网民发视频称，她在宜春丰城中医院工作五年，因肺癌向医院请病假却遭到拒绝。 经调查了解，陈某系中医院ICU护士，在今年职工体检中发现肺部疾病，中医院批准其一个月病假赴上 海诊疗。病假结束后，陈某再赴上海复查，医生出具休息14天的门诊疾病证明书。陈某向中医院提出再 休一个月病假的申请，因其未能提供需住院治疗的证明，中医院根据医院请假制度规定，给予了其一个 月的事假，但在沟通过程中出现意见分歧。 12月8日上午，市卫健委、中医院相关负责同志已与陈某夫妇见面，听取他们的意见，现场解决了其请 病假等实际问题。市卫健委对中医院相关领导语气生硬等问题提出了严肃批评，取得了当事人的理解。 后续我们将积极改进工作，切实加强对职工的人文关怀，不断提升管理服务水平。 新京报讯 12月8日，丰城市卫生健康委员会发布情况通报，内容如下： 12月7日17时许，丰城市中医院职工陈某发布了"在这个单位工作五年，却连个病假都批不了"视频，引 发社会关注。市卫健委立即开展核实处理。 ...

齐鲁晚报.齐鲁壹点郭纪轩通讯员王坤鹏 近日，由中国人民解放军北部战区总医院牵头、国内顶尖机构联合承担的"冠心病患者出凝血风险精准 分层和优化策略研究"项目，正式获批立项为国家科技重大专项。济医附院心内科凭借在心脑血管疾病 诊疗领域的扎实临床基础与科研积淀，成功跻身该国家级重大课题参与单位之列，这标志着医院临床研 究能力与学术影响力获得了国家级平台的认可，正式融入服务国家重大战略需求的科研攻坚体系。 未来，医院将继续以服务健康中国战略为引领，积极争取和融入更多国家级、省部级高水平科研项目与 平台，不断加强有组织的科研，推动临床诊疗水平与创新能力双提升，为保障区域百姓健康、助力我国 医学科技进步作出新的更大贡献。 该项目旨在建立全国性的风险分层标准与优化治疗策略，对于提升冠心病整体诊疗水平、改善患者远期 预后具有重大意义。能够参与此类国家级高水平、多中心临床研究，是对我院心内科及相关团队长期以 来在临床科研与实践方面工作的充分肯定。此次入选国家科技重大专项参与单位，是该院坚持"科教兴 院"、深化内涵建设、积极参与高水平学术合作的重要成果。医院始终坚持以临床问题为导向，积极融 入国家与区域创新网络，通过与顶尖医疗中 ...